Markets

Tis the season for big biotechs: Gossamer Bio files for a $265 million IPO

A generic image of a person stacking coins next to a calculator.
Credit: Shutterstock photo

Gossamer Bio, which is developing immunology-based therapeutics for several indications, filed on Friday with the SEC to raise up to $265 million in an initial public offering.

Gossamer's initial filing comes on the heels of an IPO from another large biotech, Moderna ( MRNA ), which finished Friday at $14.47 (-37% below issue).

The San Diego, CA-based biotech was founded in 2015 and commenced operations in 2017. The pre-revenue company booked a net loss of $7 million during 2017, and a net loss of $108 million during the nine months ended September 30, 2018.

Gossamer plans to list on the Nasdaq under the symbol GOSS. It filed confidentially on October 11, 2018. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Tis the season for big biotechs: Gossamer Bio files for a $265 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More